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Cell of Origin and Epidemiology
Multiple myeloma (MM) is a hematological malignancy characterized by abnormal accumulation of clonal plasma cells (PCs) in the bone marrow (BM). MM accounts for 10% 
of hematological malignancies and 1.6% of all U.S. cancer deaths. The median age at diagnosis is 69. Signifi cant prevalence differences are observed between age, gender, 
and race, suggesting a genetic predisposition to MM. In most cases, MM is preceded by a pre-malignant condition, monoclonal gammopathy of undetermined signifi cance 
(MGUS), followed by an asymptomatic phase, called smoldering myeloma (SMM). The risk of progression to MM is estimated 0.5%–1% per year for the heavy chain and 0.3% 
for the light chain MGUS.
Diagnosis and Clinical Presentation
The presence of a serum monoclonal protein <30 g/L, clonal BM PCs <10%, and absence of disease-related end-organ damage including calcium elevation, renal insuf-
fi ciency, anemia, and bone disease (“CRAB criteria”) defi nes MGUS. Increased number of BM PCs (10%–60%) or serum/urinary monoclonal protein exceeding MGUS limits 
defi nes the transition to SMM. MM is defi ned by BM PCs >10% and the presence of CRAB criteria. Patients require MM therapy regardless of the presence of CRAB criteria if 
BM PC ≥ 60%, the involved/uninvolved serum free light chain ratio is > 100, or focal BM lesions are identifi ed by MRI. Increased osteoclastic and decreased osteoblastic activ-
ity is commonly present in MM leading to secondary hypercalcemia, generalized osteopenia, focal osteolytic lesions, and pathological fractures.
Genomic Abnormalities
Genetic aberrations are observed from the early stages of the disease and are key events in the establishment of the clonal PC population. The clonal architecture of MM 
is characterized by multiple independent, yet related, clones at diagnosis with shifting predominance during progression that is particularly affected by therapy. MM can be 
classifi ed into two major subtypes: hyperdiploid MM (H-MM) and non-hyperdiploid MM (NH-MM). Each group comprises approximately half of patients with very low overlap. 
H-MM exhibits non-random extra copies of multiple chromosomes, especially chromosomes 3, 5, 7, 9, 11, 15, 19, and 21. The NH-MM is mainly characterized by IgH translo-
cations, leading to the activation of proto-oncogenes located in multiple partner chromosomes such as 11p13 (CCND1; found in ~18% of patients), 4p16 (MMSET and FGFR3; 
~15%), 16q23 (MAF; ~4%), 6p21 (CCND3; ~1%), and 20q12 (MAFB; ~1%). Each of these translocations is associated with a specifi c prognostic outcome.
Nearly half of MM patients have mutations in the MAPK pathway, including KRAS (~23%), NRAS (~19%), and BRAF (~7%). Putative MM genes include DIS3 and FAM46C, 
mutated in 10% and 7%, respectively. Recurrent mutations are also found in genes of the NF-κB signaling pathway (TRAF3, CYLD), cell cycle (CCND1, RB1), and DNA damage 
response (ATM, TP53). The mutation incidence increases with disease progression, especially in TP53, which is mutated in most cases of PC leukemia. MYC dysregulation is 
found in nearly one-third of patients through chromosomal translocations, insertions, deletions, and inversions. Actionable mutations are recurrently found in KRAS, NRAS, 
BRAF, FGFR3, CCND1, IDH1, and IDH2. 
Relevant Abnormalities in Disease Prognosis and Risk Stratiﬁ cation
Deletion of 17p is a rare event at diagnosis (~10%) but becomes more common with progression. This abnormality is currently the single most important genetic prognostic 
factor in MM, irrespective of treatment, suggesting that none of the therapies have a signifi cant impact in patients with 17p13 deletion. The gene responsible has not been 
completely identifi ed, but evidence indicates TP53 as the strongest candidate. t(14;16)(q32;q23) and t(14;20)(q32;q12) are associated with aggressive disease and a negative 
outcome in MM treated with conventional, alkylator-based and high-dose chemotherapy. t(4;14)(p16;q32) is associated with intermediate outcome and aggressive clinical 
features, both at diagnosis and after either standard or high-dose chemotherapy. Bortezomib partially overcomes the negative prognostic effect of t(4;14)(p16;q32). Unbal-
anced translocations with loss of the der14 (FGFR3) are commonly observed, suggesting that MMSET, and not FGFR3, may play a critical role in the clonal expansion of t(4;14)
(p16.3;q32) MM cells. 1q21 gain is seen in one-third of MM cases and has been associated with intermediate risk. The proposed target of this region is CKS1B. t(11;14)(q13;q32) 
is associated with low PC proliferation, low levels of serum monoclonal proteins, and good prognosis.
Hypodiploidy is associated with intermediate risk, whereas H-MM is associated with good prognosis.
Several gene expression profi ling (GEP) indices have been implemented in MM to perform risk stratifi cation. Gene sets between 15 and 70 probes, mostly enriched on 
proliferation genes, are currently used to identify the 15%–20% of newly diagnosed patients with a very poor prognosis.
Recent data suggest that MYC translocations and mutations in TP53, CCND1, ATM, ATR, and ZFHX4 had a negative impact in MM. Conversely, mutations in IRF4 and EGR1 
showed a positive impact on survival.
Prognosis
Risk stratifi cation is mainly based on the existence of genetic alterations and clinical parameters including serum albumin, beta-2 microglobulin level (international staging 
system), LDH, and PC proliferation rate. Presence of extramedullary disease, high tumor burden, preexisting comorbidities, age, and compromised organ function are further 
prognostic markers.
Treatment
The era of novel drugs revolutionized MM treatment, including immunomodulatory drugs (IMiDs; Thalidomide, Lenalidomide, Pomalidomide) and proteasome inhibitors 
(Bortezomib, Carfi lzomib) as the main representatives. The mechanisms of action of IMiDs have been recently elucidated, identifying the molecule recognized by the drug 
(CRBN) as well as key downstream biological effects. A remarkable number of additional drugs either were recently introduced in the clinic (HDAC inhibitor Panobinostat) or 
are under investigation (monoclonal antibodies, immunotherapies, and other targeted therapies).
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